NICE Reverses Stance On BMS' HCV Pill Daklinza
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has reversed its previous position to limit use of Bristol-Myers Squibb Company's HCV pill Daklinza to only patients with genotypes 1 and 4 without cirrhosis. It now says in final draft guidance issued Oct. 16 that presentations made by the US drug maker since that preliminary draft opinion was issued in July has convinced the HTA to include genotype 3 patients in Daklinza's label.